News

Modulight Biotherapeutics Secures $12M for Groundbreaking Therapy

Modulight Biotherapeutics Secures $12M for Groundbreaking Therapy

Significant Funding to Advance Neurological Treatments

Modulight Biotherapeutics, an innovative developer in the field of optogenetic therapies aimed at treating neurological disorders, is thrilled to announce it has successfully closed its seed funding round, raising an impressive $12.2 million. This funding will provide crucial resources to accelerate the development of the company’s optogenetic technology platform and propel the therapeutic product pipeline towards clinical stages.

Key Investors and Their Confidence

This funding round was notably led by distinguished investors including Jibe Ventures and LocalGlobe. They were joined by other significant players in the investment community such as Nexus Neurotech Ventures, RedSeed VC, Secret Chord Ventures, Fresh Fund, Saras Capital, SilverArc Capital, and Sha'ar Mivnim. The collective confidence from these partners underlines the notable potential of Modulight’s vision and strategy in the neurotechnology space.

Modulight Biotherapeutics' Vision for Neurological Solution

According to Dr. Yotam Eldar, CEO of Modulight Biotherapeutics, this funding signifies a major milestone for the company as it advances its mission to develop light-based therapeutics for severe neurological diseases. By enhancing the preclinical development of its optogenetic switch, the company can lay the groundwork for treating conditions such as trigeminal pain, enabling meaningful discussions with regulatory bodies like the FDA.

Foundation of Breakthrough Technologies

John Propst, Principal at Nexus NeuroTech Ventures, expressed excitement about investing in Modulight’s innovative approach. He highlighted the groundbreaking potential of the optogenetic neuromodulation platform, which offers a unique method to target neural circuits with exceptional precision—addressing a significant gap in treatments for neurological conditions driven by neuronal hyperexcitability.

Understanding the Optogenetic Platform

Modulight's optogenetics platform is at the forefront of developing technologies for precise and targeted treatments of neurological disorders. By distinguishing dysfunctional neuronal activity and modulating it accurately, the company aims to offer revolutionary therapies to patients suffering from chronic conditions.

The Complexity of the Brain

The human brain is a complex network comprising over 86 billion neurons. Traditional treatments often affect broad brain regions indiscriminately, demonstrating the necessity for more targeted solutions. Modulight’s approach utilizes light-sensitive proteins, known as opsins, enabling modulation of neuronal activity with great accuracy. The ability to adjust brain networks responsible for debilitating disorders such as severe chronic pain and movement disorders marks a significant advancement in the medical field.

Innovative Therapeutic Developments

Modulight is particularly focused on using eOPN3, a proprietary and biostable inhibitory opsin designed for clinical purposes. This technology allows for pathway-specific modulation, making it a versatile therapy for various neurological conditions. Early preclinical studies have shown that eOPN3 provides a high level of efficacy across several animal models dealing with pain and epilepsy. One primary area of investigation is its application for treating trigeminal pain—a severe condition often resistant to traditional drug therapies. Such advancements indicate a real possibility of providing relief through a straightforward outpatient delivery method.

Pioneering New Medical Frontiers

Modulight Biotherapeutics aims to redefine treatment paradigms for patients facing neurological challenges by pioneering a new realm of medicine that is swift, precise, and has fewer side effects. The Company’s approach revolves around modulating neuronal activity through light-activated proteins specifically targeted at pathological cells and neural pathways; a true game-changer in achieving therapeutic efficacy.

Company Contact Information

For further inquiries, Tsipi Haitovsky serves as the Global Media Liaison. She can be reached directly at +972-525-989892 for media-related questions and discussions surrounding this groundbreaking initiative.

Frequently Asked Questions

What is Modulight Biotherapeutics' recent funding milestone?

Modulight Biotherapeutics has recently secured $12.2 million in seed funding.

What is the primary focus of Modulight's technology?

The focus is on developing optogenetic therapies for treating neurological disorders by modulating neuronal activity with precision.

Who are some key investors in Modulight's funding round?

Key investors include Jibe Ventures, LocalGlobe, and Nexus Neurotech Ventures, among others.

What is the significance of eOPN3 in Modulight's research?

eOPN3 is a proprietary opsin that allows for precise neuromodulation and is being tested for its efficacy in treating trigeminal pain.

How does Modulight's approach differ from traditional treatments?

The approach targets specific neuronal activity with light, in contrast to traditional methods that affect broad brain regions indiscriminately.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Bioretec's Innovative Annual Report Showcases New Progress

Updated Category News Views 188

Bioretec Ltd's Annual Report Overview Bioretec Ltd has recently published its annual report for 2024, offering insights into the company's growth and achievements over the past year. This report showcases the advancements made in biodegradable orthopedic implants, positioning the company at the forefront of innovative healthcare solutions. Company Highlights Bioretec...

Continue Reading
Market Overview: Asia Stocks See Fluctuations Amid Election Fears

Updated Category News Views 251

Market Dynamics in Asia: A Closer Look In recent trading sessions, Asian stocks demonstrated muted movements in response to an absence of compelling trading signals, while Japanese shares experienced a notable decline driven by impending democratic choices. Investors are particularly focused on the Japanese electoral scene, which is expected to significantly influence...

Continue Reading
TScan Therapeutics Secures $52.5 Million Loan to Support Growth

Updated Category News Views 113

TScan Therapeutics Secures $52.5 Million Loan from Silicon Valley Bank WALTHAM, Mass. — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment, has announced an exciting milestone. The company has entered into a term loan facility with Silicon Valley Bank (SVB) that offers up to...

Continue Reading
Celebrating Four Years of SpaceX's Starlink Internet Service

Updated Category News Views 385

Four Years of Starlink Connectivity Four years ago, SpaceX, under the visionary leadership of Elon Musk, began its journey in satellite internet services by activating Starlink for its first paying customer. This significant milestone was established on a date that marks the beginning of a transformative era for internet connectivity. Impact of Starlink on Global Internet...

Continue Reading
AllenComm Receives Esteemed Recognition in eLearning Field

Updated Category News Views 167

AllenComm Earns Top Honor for eLearning Localization AllenComm, a prominent player in the realm of innovative learning experiences, has recently been recognized as one of the Top Content Providers for eLearning Localization by a well-regarded industry source. This accolade reflects the company's dedication to delivering high-quality, effective educational solutions that...

Continue Reading